Interstitial lung diseases (ILDs) represent an extensive group of pulmonary disorders, characterized by inflammation and fibrosis of the lung interstitium. This article provides a comprehensive overview of ILDs, their etiology, clinical manifestations, diagnostic tools, and treatment options.
ILDs can be idiopathic or associated with various conditions such as connective tissue diseases, environmental exposures, and certain medications. Idiopathic pulmonary fibrosis (IPF) is the most common form of ILDs. Other types include nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, and hypersensitivity pneumonitis.
Patients with ILDs typically present with progressive dyspnea and non-productive cough. Physical examination may reveal bibasilar inspiratory crackles and finger clubbing. Pulmonary function tests often show a restrictive pattern with reduced diffusion capacity for carbon monoxide.
High-resolution computed tomography (HRCT) is the imaging modality of choice for ILDs. It can identify characteristic patterns such as honeycombing, ground-glass opacities, and traction bronchiectasis. In certain cases, a lung biopsy may be necessary for definitive diagnosis.
Treatment of ILDs is primarily aimed at reducing inflammation and fibrosis, and managing symptoms. Corticosteroids and immunosuppressive agents are commonly used. For IPF, specific antifibrotic agents such as pirfenidone and nintedanib have shown efficacy. Lung transplantation may be considered for suitable candidates.
ILDs are complex disorders requiring a comprehensive diagnostic approach and individualized treatment strategies. Early recognition and appropriate management can significantly improve patient outcomes. Continued research is necessary to further our understanding of these diseases and develop more effective therapeutic options.
1.
Chemo-Free Triplet Yields 68% Response Rate in Richter Transformation
2.
Can Fasting Around Chemo Improve Ovarian Cancer Outcomes?
3.
Chemo causes lasting physical decline in breast cancer survivors
4.
MRI-guided radiation therapy improves quality of life with fewer side effects in patients with localized cancer. JAMA
5.
BMI is linked to heart damage from chemotherapy in breast cancer patients.
1.
The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond
2.
Rehabilitation Following Bone Marrow Functional Suppression: Clinical Strategies and Advances
3.
Unlocking the Potential of Cancer Antigen 19-9 for Early Detection
4.
Strategic Breakthroughs in Oncology in Clinical Decision-Making
5.
Targeted Approaches to Breast Cancer Liver Metastases: Surgery, Ablation, and Survival Insights
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
2.
Early warning sings of camcer that need medical attention
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part I
4.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
5.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation